de la Haba J, Gómez A, Dueñas R, Ribelles N, Méndez M J, Serrano R, Font P, Aranda E
Department of Medical Oncology, University Hospital Reina Sofia, Avda. Menéndez Pidal S/N, 14004 Córdoba, Spain.
Eur J Surg Oncol. 2004 Apr;30(3):346-51. doi: 10.1016/j.ejso.2003.10.006.
Breast cancer is a disease with a very variable progression. Primary tumour size and metastatic lymph node involvement are the best indicators of the likelihood of relapse. However, their value in predicting progression following relapse is not clear.
The aim of this study was to asses whether the relationship between tumour size and the number of lymph nodes involved had any value as predictive factors of post-relapse progression.
We established an index defined as the quotient between the number of diseased lymph nodes and the tumour size (in cm).
Applying this index in 230 consecutive patients with metastatic breast cancer, we observed that there was a significant inverse relation between the index and post-relapse progression.
We conclude that, at the time of initial diagnosis, the quotient of tumour size and the number of diseased lymph nodes could be a good predictor of time-to-progression following the diagnosis of the metastatic disease.
乳腺癌是一种进展差异很大的疾病。原发肿瘤大小和转移性淋巴结受累情况是复发可能性的最佳指标。然而，它们在预测复发后进展方面的价值尚不清楚。
本研究的目的是评估肿瘤大小与受累淋巴结数量之间的关系作为复发后进展的预测因素是否有任何价值。
我们建立了一个指数，定义为患病淋巴结数量与肿瘤大小（厘米）的商。
在230例连续的转移性乳腺癌患者中应用该指数，我们观察到该指数与复发后进展之间存在显著的负相关。
我们得出结论，在初次诊断时，肿瘤大小与患病淋巴结数量的商可能是转移性疾病诊断后进展时间的良好预测指标。
